These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 19118046

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The therapeutic and preventive effect of RRR-alpha-vitamin E succinate on prostate cancer via induction of insulin-like growth factor binding protein-3.
    Yin Y, Ni J, Chen M, DiMaggio MA, Guo Y, Yeh S.
    Clin Cancer Res; 2007 Apr 01; 13(7):2271-80. PubMed ID: 17404112
    [Abstract] [Full Text] [Related]

  • 3. In vitro and in vivo anticancer effects of the novel vitamin E ether analogue RRR-alpha-tocopheryloxybutyl sulfonic acid in prostate cancer.
    Ni J, Mai T, Pang ST, Haque I, Huang K, DiMaggio MA, Xie S, James NS, Kasi D, Chemler SR, Yeh S.
    Clin Cancer Res; 2009 Feb 01; 15(3):898-906. PubMed ID: 19188160
    [Abstract] [Full Text] [Related]

  • 4. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
    Xu Y, Dalrymple SL, Becker RE, Denmeade SR, Isaacs JT.
    Clin Cancer Res; 2006 Jul 01; 12(13):4072-9. PubMed ID: 16818707
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Alpha-vitamin E derivative, RRR-alpha-tocopheryloxybutyric acid inhibits the proliferation of prostate cancer cells.
    Chang E, Ni J, Yin Y, Lin CC, Chang P, James NS, Chemler SR, Yeh S.
    Asian J Androl; 2007 Jan 01; 9(1):31-9. PubMed ID: 17187157
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Differential retention of alpha-vitamin E is correlated with its transporter gene expression and growth inhibition efficacy in prostate cancer cells.
    Ni J, Pang ST, Yeh S.
    Prostate; 2007 Apr 01; 67(5):463-71. PubMed ID: 17252538
    [Abstract] [Full Text] [Related]

  • 9. Preclinical antitumor activity of the oral platinum analog satraplatin.
    Wosikowski K, Lamphere L, Unteregger G, Jung V, Kaplan F, Xu JP, Rattel B, Caligiuri M.
    Cancer Chemother Pharmacol; 2007 Sep 01; 60(4):589-600. PubMed ID: 17541592
    [Abstract] [Full Text] [Related]

  • 10. RRR-alpha-tocopheryl succinate inhibits human prostate cancer cell invasiveness.
    Zhang M, Altuwaijri S, Yeh S.
    Oncogene; 2004 Apr 15; 23(17):3080-8. PubMed ID: 15048090
    [Abstract] [Full Text] [Related]

  • 11. Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice.
    Zheng X, Chang RL, Cui XX, Avila GE, Hebbar V, Garzotto M, Shih WJ, Lin Y, Lu SE, Rabson AB, Kong AN, Conney AH.
    Clin Cancer Res; 2006 Jun 01; 12(11 Pt 1):3444-51. PubMed ID: 16740769
    [Abstract] [Full Text] [Related]

  • 12. Vitamin D-induced up-regulation of tumour necrosis factor alpha (TNF-alpha) in prostate cancer cells.
    Golovko O, Nazarova N, Tuohimaa P.
    Life Sci; 2005 Jun 17; 77(5):562-77. PubMed ID: 15904673
    [Abstract] [Full Text] [Related]

  • 13. pH modulation using CsCl enhances therapeutic effects of vitamin D in LNCaP tumor bearing mice.
    Guns ES, Xie X, Fedoruk M, Madera C, Cowell S, Mayer LD, Skov K, Gleave ME, Kozlowski P.
    Prostate; 2005 Aug 01; 64(3):316-22. PubMed ID: 15754319
    [Abstract] [Full Text] [Related]

  • 14. Vitamin E succinate induces apoptosis in human prostate cancer cells: role for Fas in vitamin E succinate-triggered apoptosis.
    Israel K, Yu W, Sanders BG, Kline K.
    Nutr Cancer; 2000 Aug 01; 36(1):90-100. PubMed ID: 10798221
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089.
    Lokeshwar BL, Schwartz GG, Selzer MG, Burnstein KL, Zhuang SH, Block NL, Binderup L.
    Cancer Epidemiol Biomarkers Prev; 1999 Mar 01; 8(3):241-8. PubMed ID: 10090302
    [Abstract] [Full Text] [Related]

  • 16. Vitamin D compounds: clinical development as cancer therapy and prevention agents.
    Trump DL, Muindi J, Fakih M, Yu WD, Johnson CS.
    Anticancer Res; 2006 Mar 01; 26(4A):2551-6. PubMed ID: 16886663
    [Abstract] [Full Text] [Related]

  • 17. In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells.
    Qian DZ, Ren M, Wei Y, Wang X, van de Geijn F, Rasmussen C, Nakanishi O, Sacchi N, Pili R.
    Prostate; 2005 Jun 15; 64(1):20-8. PubMed ID: 15651062
    [Abstract] [Full Text] [Related]

  • 18. Vitamin E succinate inhibits NF-kappaB and prevents the development of a metastatic phenotype in prostate cancer cells: implications for chemoprevention.
    Crispen PL, Uzzo RG, Golovine K, Makhov P, Pollack A, Horwitz EM, Greenberg RE, Kolenko VM.
    Prostate; 2007 May 01; 67(6):582-90. PubMed ID: 17262802
    [Abstract] [Full Text] [Related]

  • 19. 1,24(S)-dihydroxyvitamin D2, an endogenous vitamin D2 metabolite, inhibits growth of breast cancer cells and tumors.
    Zinser GM, Tribble E, Valrance M, Urben CM, Knutson JC, Mazess RB, Strugnell SA, Welsh J.
    Anticancer Res; 2005 May 01; 25(1A):235-41. PubMed ID: 15816543
    [Abstract] [Full Text] [Related]

  • 20. The antitumor effect of lowered doses of cytostatics combined with new analogs of vitamin D in mice.
    Wietrzyk J, Nevozhay D, Filip B, Milczarek M, Kutner A.
    Anticancer Res; 2007 May 01; 27(5A):3387-98. PubMed ID: 17970085
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.